Concentrate Product Sales - Point-In-Time was Rockwell Medical’s largest revenue line in fiscal 2025, bringing in $68.93M of $69.26M (100%).
| Timing Of Transfer Of Good Or Service | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Concentrate Product Sales - Point-In-Time | — | — | $101.44M | $68.93M | ||||
| Product Sales – Point-In-Time | — | $79.80M | — | — | ||||
| Product Sales - Point-In-Time | $72.55M | — | — | — | ||||
| Point-In-Time | — | — | — | — | ||||
| License Fee – Over Time | $256.00K | $3.81M | $46.00K | $325.00K | ||||
| Over-Time | — | — | — | — | ||||
| Total | $72.81M | $83.61M | $101.49M | $69.26M |
Rockwell Medical brought in $69.26M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That was down 31.8% from $101.49M in fiscal 2024. Concentrate Product Sales - Point-In-Time was the largest at $68.93M (99.5%), ahead of License Fee – Over Time at $325.00K (0.5%).
Rockwell Medical began breaking out Concentrate Product Sales - Point-In-Time in fiscal 2024, when it brought in $101.44M. Rockwell Medical stopped reporting Product Sales – Point-In-Time ($79.80M in fiscal 2023) and Product Sales - Point-In-Time ($72.55M in fiscal 2022) as separate revenue lines.
U.S was Rockwell Medical’s largest region in fiscal 2025, bringing in $60.36M of $69.26M (87%).
| Geography | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| U.S | $65.77M | $74.34M | $92.26M | $60.36M | |||||
| United States | — | — | — | — | |||||
| Rest Of World | $7.05M | $9.27M | $9.23M | $8.90M | |||||
| Non-Us | — | — | — | — | |||||
| Total | $72.81M | $83.61M | $101.49M | $69.26M |
Rockwell Medical brought in $69.26M from its two regions in fiscal 2025, the year ended December 31, 2025. That was down 31.8% from $101.49M in fiscal 2024. U.S was the largest at $60.36M (87.1%), ahead of Rest Of World at $8.90M (12.9%).
Compared with fiscal 2024, Rest Of World fell 3.6% to $8.90M and U.S fell 34.6% to $60.36M. From fiscal 2022 to 2025, combined revenue from these regions fell from $72.81M to $69.26M, a compound annual decline of 1.7%. U.S's share of the total fell from 90.3% to 87.1%.
Concentrate Products Sales was Rockwell Medical’s largest product and service line in fiscal 2024, bringing in $101.44M of $101.49M (100%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|---|---|---|
| Concentrate Products Sales | — | — | — | $101.44M | ||||
| Concentrate Products | — | — | $81.27M | — | ||||
| Concentrate Product Sales | $58.91M | $69.16M | — | — | ||||
| Concentrate Product License Fee | $1.94M | $2.49M | — | — | ||||
| Drug Revenues | — | — | $2.34M | — | ||||
| Drug Revenue | — | — | — | — | ||||
| Drug Product Sales | $835.00K | $903.00K | — | — | ||||
| Drug License Fee | $241.00K | $256.00K | — | — | ||||
| License Fees | — | — | — | $46.00K | ||||
| Total | $61.93M | $72.81M | $83.61M | $101.49M |
Rockwell Medical brought in $101.49M from its two product and service lines in fiscal 2024, the year ended December 31, 2024. Rockwell Medical regrouped these lines after fiscal 2023, so the total does not compare directly with that year's $83.61M. Concentrate Products Sales was the largest at $101.44M (100.0%), ahead of License Fees at $46.00K (0.0%).
Rockwell Medical began breaking out Concentrate Products Sales in fiscal 2024 and License Fees in fiscal 2024. Rockwell Medical stopped reporting Concentrate Products ($81.27M in fiscal 2023), Concentrate Product Sales ($69.16M in fiscal 2022), Concentrate Product License Fee ($2.49M in fiscal 2022) and three others as separate lines.
Rockwell Medical (RMTI) reports its revenue by timing of transfer of good or service, by geography and by product and service. In fiscal 2025, Concentrate Product Sales - Point-In-Time was its largest revenue line, bringing in $68.93M (99.5% of the total), followed by License Fee – Over Time at $325.00K (0.5%).
Concentrate Product Sales - Point-In-Time was Rockwell Medical's largest revenue line in fiscal 2025, bringing in $68.93M, or 99.5% of the $69.26M total across its two revenue lines.
U.S was Rockwell Medical's largest region in fiscal 2025, bringing in $60.36M, or 87.1% of the $69.26M total across its two regions.
Concentrate Products Sales was Rockwell Medical's largest product and service line in fiscal 2024, bringing in $101.44M, or 100.0% of the $101.49M total across its two product and service lines.
Every figure comes from Rockwell Medical's annual financial filings, as reported. Each line keeps the name Rockwell Medical gives it, and years follow its fiscal calendar.
Rockwell Medical's revenue by timing of transfer of good or service goes back to fiscal 2018, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.